Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06295432 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 2025 to Dec 2026 Study sites: 1 to 4v5 Show 1 more changeShow less
    • Study sites: 1 to 4
  2. Primary and study completion dates: Jun 2025 to Dec 2025v4
  3. Re-verified, no change to tracked fieldsv3
  4. Primary endpoint revisedv2 See this version in full on ClinicalTrials.gov ↗
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
DZD9008 in combination with AZD4205 for the treatment of patients with advanced NSCLC with EGFR mutations who have progressed after standard treatment. The purpose of this study is to assess the safety and efficacy of this combination therapy.
Trial Details
NCT Number NCT06295432
Lead Sponsor Dizal Pharmaceuticals
Conditions Non-small Cell Lung Cancer
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov